Revumenib (SNDX-5613)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Revumenib (SNDX-5613), covering 2026-04-14 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) [Phase 1, Phase 2]